Asian Spectator


The Times

.

Guangdong Goods Go Global Promotional Video Released, Extending an Invitation to the World from Guangdong

SHENZHEN, CHINA – Media OutReach Newswire – 18 November 2026 – On November 18–19, the 33rd APEC Economic Leaders' Meeting kicks off in Shenzhen, drawing global attention to Gu...

Suncheon, Korea's ecological capital, aims to draw 10 million ...

SUNCHEON, South Korea, July 11, 2019 /PRNewswire-AsiaNet/-- Suncheon City Hall has launched a "Visit Suncheon Year" campaign this year in Suncheon, a southwestern city known as South Korea's...

HKSTP Takes Nine Game-Changing AI Tech Ventures to WAIC 2025 to Advance China's AI Plus Vision in Transforming Business and Industry

HONG KONG SAR / SHANGHAI, CHINA - Media OutReach Newswire - 27 July 2025 - Hong Kong Science and Technology Parks Corporation (HKSTP) is embarking on a mission to advance China's AI Plus vi...

Tokyo 2020 Olympic Games - Jumping Preview

LAUSANNE, Switzerland, July 23, 2021 /PRNewswire-AsiaNet/ -- Jumping looks set to be a testing thrillerTokyo 2020 is one of the most talked-about Olympic Games of all time, and as it arrives...

2021 VIB AGM: Focus on core products and services with high te...

HO CHI MINH CITY, Vietnam, April 5, 2021 /PRNewswire-Asianet/ -- Vietnam International Bank (VIB, Vietnam - Stock code: VIB) held the 2021 Annual General Meeting of Shareholders on March 24...

Suntrap Discovered 'LeSoleil' for COVID-19 and the Epidemic

Guangzhou, China, Feb 14, 2021 - (ACN Newswire) - AI-assisted computing has greatly improved the efficiency of new drug research and development. Suntrap Life Technologies Co., Ltd has take...

For You Rehab Responds to Primary Healthcare Blueprint and Champions Direct Access Physiotherapy to Alleviate Public Healthcare Strain

Founder Reveals Youthful Trend in Pain Conditions; Improving Service Efficiency through Precision Diagnostics and Integrity-Driven RehabilitationHONG KONG SAR - Media OutReach Newswire - 5 ...

Xinhua Silk Road: Sheng Hong Holding Group launches new energy...

BEIJING, Feb. 2, 2023 /PRNewswire-AsiaNet/ -- Sheng Hong Holding Group, a leading high-tech enterprise in Suzhou, signed a contract to settle its battery gigafactory and new energy research ...

Orocobre Limited Results Of General Meeting

BRISBANE, Australia, Feb. 27, 2018 /PRNewswire-AsiaNet/ -- Orocobre Limited (ASX: ORE, TSX: ORL ) ("Orocobre" or "the Company") wishes to announce that all resolutions were passed as ordinar...

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

TOKYO, Jul 9, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).The applications were based on data from the Phase 1b Study 116/KEYNOTE-524 trial, which showed clinically meaningful efficacy in the single-arm setting. These data were recently presented at the 2020 American Society of Clinical Oncology Annual Meeting and supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Eisai's and Merck's applications, another combination therapy was approved based on a randomized controlled trial that demonstrated overall survival. Consequently, the CRL stated that the applications do not provide evidence that KEYTRUDA in combination with LENVIMA represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for Study 116/KEYNOTE-524 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the LENVIMA plus KEYTRUDA combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the currently approved indications for LENVIMA or for KEYTRUDA.Eisai and Merck are continuing to evaluate the LENVIMA plus KEYTRUDA combination across 13 different tumor types in 18 clinical trials including the LEAP (LEnvatinib And Pembrolizumab) clinical program.

For more information, visit https://www.eisai.com/news/2020/news202039.html.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
  
Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations
Pamela Eisele: (267) 305-3558
Michael Close: (267) 305-1211

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegaluk casinos not on gamstophttps://www.capitolcitycinema.org/canlı casino siteleriStreamEastStreamEastjojobetcialis 20 mg fiyat